DEPDC1B is involved in the proliferation, metastasis, cell cycle arrest and apoptosis of colon cancer cells by regulating NUP37

Xiong,Hui; Li,Yun; Liu,Manhua

doi:10.3892/mmr.2023.13013

DEPDC1B is involved in the proliferation, metastasis, cell cycle arrest and apoptosis of colon cancer cells by regulating NUP37

Authors:
- Hui Xiong
- Yun Li
- Manhua Liu
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of General Surgery, The First Affiliated Hospital of Nanchang University Jing'an County People's Hospital, Jing'an, Shanghai 330600, P.R. China
Published online on: May 16, 2023 https://doi.org/10.3892/mmr.2023.13013
Article Number: 126
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that DEP domain protein 1B (DEPDC1B) serves several roles in the occurrence and development of various types of cancer. Nevertheless, the effect of DEPDC1B on colorectal cancer (CRC), as well as its particular underlying molecular mechanism remain to be elucidated. In the present study, the mRNA and protein expression levels of DEPDC1B and nucleoporin 37 (NUP37) in CRC cell lines were assessed by reverse transcription‑quantitative PCR and western blotting, respectively. Cell Counting Kit‑8 and 5‑Ethynyl‑2'‑deoxyuridine assays were carried out to determine cell proliferation. In addition, the migration and invasion abilities of cells were evaluated using wound healing and Transwell assays. The changes in cell apoptosis and cell cycle distribution were assessed by flow cytometry and western blotting. Bioinformatics analysis and co‑immunoprecipitation assays were performed to predict and verify, respectively, the binding capacity of DEPDC1B on NUP37. The expression levels of Ki‑67 were detected by immunohistochemical assay. Finally, the activation of phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT) signaling was measured using western blotting. The results showed that DEPDC1B and NUP37 were upregulated in CRC cell lines. DEPDC1B and NUP37 silencing both inhibited the proliferation, migration and invasion capabilities of CRC cells and promoted cell apoptosis and cell cycle arrest. Furthermore, NUP37 overexpression reversed the inhibitory effects of DEPDC1B silencing on the behavior of CRC cells. Animal experiments demonstrated that DEPDC1B knockdown inhibited the growth of CRC in vivo by targeting NUP37. In addition, DEPDC1B knockdown inhibited the expression levels of the PI3K/AKT signaling‑related proteins in CRC cells and tissues by also binding to NUP37. Overall, the current study suggested that DEPDC1B silencing could alleviate the progression of CRC via targeting NUP37.

View Figures

View References

1	Li J, Ma X, Chakravarti D, Shalapour S and DePinho RA: Genetic and biological hallmarks of colorectal cancer. Genes Dev. 35:787–820. 2021. View Article : Google Scholar : PubMed/NCBI
2	Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M and Saad A: Colorectal cancer epidemiology: Recent trends and impact on outcomes. Curr Drug Targets. 22:998–1009. 2021. View Article : Google Scholar : PubMed/NCBI
3	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019. View Article : Google Scholar : PubMed/NCBI
4	Heinimann K: Hereditary colorectal cancer: Clinics, diagnostics and management. Ther Umsch. 75:601–606. 2018.(In German). View Article : Google Scholar : PubMed/NCBI
5	Zielińska A, Włodarczyk M, Makaro A, Sałaga M and Fichna J: Management of pain in colorectal cancer patients. Crit Rev Oncol Hematol. 157:1031222021. View Article : Google Scholar : PubMed/NCBI
6	Sinha R: Colorectal cancer. Clin Radiol. 76:8702021. View Article : Google Scholar : PubMed/NCBI
7	Wang L, Tang L, Xu R, Ma J, Tian K, Liu Y, Lu Y, Wu Z and Zhu X: DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5. Cell Death Dis. 12:7532021. View Article : Google Scholar : PubMed/NCBI
8	Figeac N, Pruller J, Hofer I, Fortier M, Ortuste Quiroga HP, Banerji CRS and Zammit PS: DEPDC1B is a key regulator of myoblast proliferation in mouse and man. Cell Prolif. 53:e127172020. View Article : Google Scholar : PubMed/NCBI
9	Bai S, Chen T, Du T, Chen X, Lai Y, Ma X, Wu W, Lin C, Liu L and Huang H: High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer. Oncol Lett. 14:6801–6808. 2017.PubMed/NCBI
10	Pollino S, Benassi MS, Pazzaglia L, Conti A, Bertani N, Righi A, Piccinni-Leopardi M, Picci P and Perris R: Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas. Histol Histopathol. 33:597–608. 2018.PubMed/NCBI
11	Zhang F and Zhou Q: Knockdown of BRCC3 exerts an anti-tumor effect on cervical cancer in vitro. Mol Med Rep. 18:4886–4894. 2018.PubMed/NCBI
12	Xu Y, Sun W, Zheng B, Liu X, Luo Z, Kong Y, Xu M and Chen Y: DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. Exp Cell Res. 379:48–54. 2019. View Article : Google Scholar : PubMed/NCBI
13	Su YF, Liang CY, Huang CY, Peng CY, Chen CC, Lin MC, Lin RK, Lin WW, Chou MY, Liao PH and Yang JJ: A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK. J Biomed Sci. 21:672014. View Article : Google Scholar : PubMed/NCBI
14	Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X, Yuan J and Li M: DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/β-catenin signaling. Biochem Biophys Res Commun. 450:899–905. 2014. View Article : Google Scholar : PubMed/NCBI
15	Walther TC, Alves A, Pickersgill H, Loïodice I, Hetzer M, Galy V, Hülsmann BB, Köcher T, Wilm M, Allen T, et al: The conserved Nup107-160 complex is critical for nuclear pore complex assembly. Cell. 113:195–206. 2003. View Article : Google Scholar : PubMed/NCBI
16	Huang L, Wang T, Wang F, Hu X, Zhan G, Jin X, Zhang L and Li Y: NUP37 silencing induces inhibition of cell proliferation, G1 phase cell cycle arrest and apoptosis in non-small cell lung cancer cells. Pathol Res Pract. 216:1528362020. View Article : Google Scholar : PubMed/NCBI
17	Zhang J, Lv W, Liu Y, Fu W, Chen B, Ma Q, Gao X and Cui X: Nucleoporin 37 promotes the cell proliferation, migration, and invasion of gastric cancer through activating the PI3K/AKT/mTOR signaling pathway. In Vitro Cell Dev Biol Anim. 57:987–997. 2021. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	National Research Council (US), . Committee for the update of the guide for the care and use of laboratory animals: The national academies collection: Reports funded by national institutes of health. Guide for the care and use of laboratory animals. 8th edition. National Academies Press (US), National Academy of Sciences; Washington, DC: 2011, PubMed/NCBI
20	Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal Carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18:2017. View Article : Google Scholar
21	Johdi NA and Sukor NF: Colorectal cancer immunotherapy: Options and strategies. Front Immunol. 11:16242020. View Article : Google Scholar : PubMed/NCBI
22	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
23	Xie YH, Chen YX and Fang JY: Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 5:222020. View Article : Google Scholar : PubMed/NCBI
24	Marchesi S, Montani F, Deflorian G, D'Antuono R, Cuomo A, Bologna S, Mazzoccoli C, Bonaldi T, Di Fiore PP and Nicassio F: DEPDC1B coordinates de-adhesion events and cell-cycle progression at mitosis. Dev Cell. 31:420–433. 2014. View Article : Google Scholar : PubMed/NCBI
25	Sun Y and Zhang Z: In silico identification of crucial genes and specific pathways in hepatocellular cancer. Genet Test Mol Biomarkers. 24:296–308. 2020. View Article : Google Scholar : PubMed/NCBI
26	Li Z, Wang Q, Peng S, Yao K, Chen J, Tao Y, Gao Z, Wang F, Li H, Cai W, et al: The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling. Clin Transl Med. 10:e1912020. View Article : Google Scholar : PubMed/NCBI
27	Lai CH, Xu K, Zhou J, Wang M, Zhang W, Liu X, Xiong J, Wang T, Wang Q, Wang H, et al: DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1. Cell Death Dis. 11:9862020. View Article : Google Scholar : PubMed/NCBI
28	Liu X, Li T, Huang X, Wu W, Li J, Wei L, Qian Y, Xu H, Wang Q and Wang L: DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway. Oncol Lett. 20:1462020. View Article : Google Scholar : PubMed/NCBI
29	Yuan Y, Ping W, Zhang R, Hao Z and Zhang N: DEPDC1B collaborates with GABRD to regulate ESCC progression. Cancer Cell Int. 22:2142022. View Article : Google Scholar : PubMed/NCBI